Veterinary Vaccine Market Analysis, Size, Share, Demand Forecast 2033
Veterinary Vaccine Market Research Report By Route of Administration (Intramuscular, Subcutaneous, Intranasal), By Animal Type (Companion, Livestock), By Product (Inactivated Vaccines, Attenuated Live Vaccines, DNA Vaccines, Subunit Vaccines, Recombinant Vaccines), and By Region: Analysis and Forecast 2024-2033
- Description
- Table of Content
- Methodology
- Key-Players
Description
Veterinary Vaccine Market: Overview
The global Veterinary Vaccine market size generated approximately $8.52 Billion in revenue in 2023 and is projected to reach $15.15 Billion by 2033, reflecting a forecasted compound annual growth rate (CAGR) of 6%.
Veterinary vaccines are biological agents designed to protect animal health and well-being. Similar to human vaccines, they play a crucial role in preventing diseases in animals, which in turn helps protect humans due to the interconnectedness of the ecological food chain. The primary purpose of veterinary vaccines is to ensure the welfare of companion animals while also promoting cost-effective and safe livestock production. Additionally, these vaccines help prevent the transmission of diseases from animals to humans. Due to the distinct goals, the development of vaccines for animals requires different approaches, ranging from crude vaccines to more advanced subunit vaccines and naked DNA injections. The first veterinary vaccine was developed in 1879 for chicken cholera, marking the beginning of significant research and development in this field.
Veterinary Vaccine Market: Growth Drivers
Increased Government Efforts for Livestock Safety
The global veterinary vaccine market is expected to grow due to increased efforts by regional governments to safeguard livestock from deadly diseases. In the wake of the COVID-19 pandemic, believed to have originated from bats, many countries have intensified the implementation of existing animal health laws. For instance, the Animal and Plant Health Inspection Service (APHIS) of the United States Department of Agriculture has highlighted the 2018 Farm Bill, which supports animal disease prevention and management. This bill allocates funds for initiatives like the National Animal Vaccine and Veterinary Countermeasures Bank (NAVVCB) and the National Animal Disease Preparedness and Response Program (NADPRP), further reinforcing animal health policies.
Growing Cases of Animal-to-Human Disease Transmission to Drive Further Growth
Recent research highlights the increasing incidence of diseases transmitted from animals to humans, particularly from livestock. These zoonotic diseases include campylobacteriosis, ringworm, listeriosis, Q fever, chlamydiosis, rabies, yersiniosis, leptospirosis, salmonellosis, cryptosporidiosis, and infections caused by pathogens like Mycobacterium paratuberculosis, Escherichia coli, MRSA, and Anthrax. While not all of these diseases have preventive vaccines, global leaders and health agencies are focusing on controlling them at their source. For example, rabies, a deadly zoonotic disease responsible for over 50,000 deaths annually, can be prevented by administering oral anti-rabies vaccines to dogs, a method endorsed by the World Health Organization (WHO) and the World Organization for Animal Health (OIE).
Veterinary Vaccine Market: Challenges
Lack of Supporting Infrastructure
One significant challenge facing the veterinary vaccine market is the insufficient ancillary infrastructure needed to implement animal vaccination policies effectively. Additionally, the high cost of certain vaccines may deter pet owners on limited budgets from vaccinating their animals, hindering market growth.
Veterinary Vaccine Market: Segmentation Analysis
The global veterinary vaccine market is segmented by the route of administration, animal type, product, and region.
- Route of Administration: The market devided into intramuscular, subcutaneous, and intranasal segments. In 2022, the subcutaneous segment accounted for the highest market share. Subcutaneous injections, typically administered behind the neck or shoulder blades, offer ease of administration and effective absorption, making them a popular choice among veterinarians.
- Animal Type: The market is segmented into companion animals and livestock, with livestock holding the largest market share. The increasing demand for meat products in fast-food chains, hotels, and other establishments has driven the growth of livestock vaccination. The rise in zoonotic diseases has also led to the widespread adoption of livestock vaccines.
- Product: The market is categorized into inactivated vaccines, attenuated live vaccines, DNA vaccines, subunit vaccines, and recombinant vaccines. In 2022, attenuated live vaccines held a significant market share, being the oldest vaccination method in use. Ongoing research into the further application of these vaccines is expected to drive growth in this segment.
The global veterinary vaccine market key Players and Segments as follows:
- Boehringer Ingelheim Animal Health
- Zoetis
- Elanco Animal Health
- Merck Animal Health
- IDEXX Laboratories
- Ceva Santé Animale
- MSD Animal Health
- Virbac
- Vetoquinol
- Heska Corporation
- Zomedica Pharmaceuticals Corp.
- HIPRA
- Biogenesis Bago
- Zoetis India Ltd.
- Biogénesis Bagó
By Route of Administration
- Intramuscular
- Subcutaneous
- Intranasal
By Animal Type
- Companion
- Livestock
By Product
- Inactivated Vaccines
- Attenuated Live Vaccines
- DNA Vaccines
- Subunit Vaccines
- Recombinant Vaccines
Report Scope:
| Report Attributes | Report Description |
|---|---|
| Report Name | Veterinary Vaccine Market Research Report |
| Market Size in 2023 | USD 8.52 Billion |
| Market Size By 2033 | USD 15.15 Billion |
| CAGR (2024-2033) | 6% |
| Base Year | 2023 |
| Historic Period | 2020 to 2022 |
| Forecast Period | 2024 – 2033 |
| Market Segments | By Route of Administration, By Animal Type, By Product, and By Region |
| Comeptitive Landscape | Boehringer Ingelheim Animal Health, Zoetis, Elanco Animal Health, Merck Animal Health, IDEXX Laboratories, Ceva Santé Animale, MSD Animal Health, Virbac, Vetoquinol, Heska Corporation, Zomedica Pharmaceuticals Corp., HIPRA, Biogenesis Bago, Zoetis India Ltd., Biogénesis Bagó |
| Regional Analysis | North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA) |
| Customization Scope | Free report customization Available after purchase. Report segments, country based Customization will be provided. Moreover, additional customization can be done based on the requirements. |
Veterinary Vaccine Market: Regional Analysis
North America Leads with One-Fourth of the Market Share in 2022
North America is expected to dominate the global veterinary vaccine market during the forecast period. In 2022, the region contributed 1/4’th of global revenue, driven by extensive livestock farming and the prevalence of various zoonotic diseases. The United States and Canada have implemented strict regulations to ensure the effective rollout and enforcement of mass animal vaccination programs. Furthermore, the presence of a robust veterinary healthcare infrastructure supports regional growth. The companion pet care sector also contributes significantly to revenue, with a growing number of pet owners in these countries.
- North America
- The U.S.
- Canada
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
- Boehringer Ingelheim Animal Health
- Zoetis
- Elanco Animal Health
- Merck Animal Health
- IDEXX Laboratories
- Ceva Santé Animale
- MSD Animal Health
- Virbac
- Vetoquinol
- Heska Corporation
- Zomedica Pharmaceuticals Corp.
- HIPRA
- Biogenesis Bago
- Zoetis India Ltd.
- Biogénesis Bagó